These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 22305321)

  • 1. Bevacizumab for ROP.
    Blair M; Shapiro MJ
    Ophthalmology; 2012 Feb; 119(2):431-2; author reply 432. PubMed ID: 22305321
    [No Abstract]   [Full Text] [Related]  

  • 2. Bevacizumab for retinopathy of prematurity.
    Stewart MW
    Ophthalmology; 2012 May; 119(5):1091-2; author reply 1092-2.e1. PubMed ID: 22551614
    [No Abstract]   [Full Text] [Related]  

  • 3. Retinopathy of prematurity in the time of bevacizumab: incorporating the BEAT-ROP results into clinical practice.
    Moshfeghi DM; Berrocal AM
    Ophthalmology; 2011 Jul; 118(7):1227-8. PubMed ID: 21724044
    [No Abstract]   [Full Text] [Related]  

  • 4. Intravitreal and intracameral bevacizumab to treat neovascular complications of retinopathy of prematurity.
    dell'Omo R; Kulkarni A; Franks WA
    Acta Ophthalmol; 2008 Sep; 86(6):698-700. PubMed ID: 18081905
    [No Abstract]   [Full Text] [Related]  

  • 5. Retinopathy of prematurity: do we still have a problem?: the Charles L. Schepens lecture.
    Tasman W
    Arch Ophthalmol; 2011 Aug; 129(8):1083-6. PubMed ID: 21825195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab for retinopathy of prematurity.
    Gole GA; Camuglia JE; Ells AL
    N Engl J Med; 2011 Jun; 364(24):2360-1; author reply 2362. PubMed ID: 21675896
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan.
    Wu WC; Yeh PT; Chen SN; Yang CM; Lai CC; Kuo HK
    Ophthalmology; 2011 Jan; 118(1):176-83. PubMed ID: 20673589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab for retinopathy of prematurity.
    Good WV; Palmer EA
    N Engl J Med; 2011 Jun; 364(24):2359; author reply 2361-2. PubMed ID: 21675899
    [No Abstract]   [Full Text] [Related]  

  • 9. [Bevacizumab].
    Taéron C
    Rev Infirm; 2009; (147):46-8. PubMed ID: 19317091
    [No Abstract]   [Full Text] [Related]  

  • 10. Avastin as monotherapy for retinopathy of prematurity.
    Mintz-Hittner HA
    J AAPOS; 2010 Feb; 14(1):2-3. PubMed ID: 20227612
    [No Abstract]   [Full Text] [Related]  

  • 11. Bevacizumab for retinopathy of prematurity.
    Gilbert CE; Zin A; Darlow B
    N Engl J Med; 2011 Jun; 364(24):2359-60; author reply 2361-2. PubMed ID: 21675898
    [No Abstract]   [Full Text] [Related]  

  • 12. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity.
    Chung EJ; Kim JH; Ahn HS; Koh HJ
    Graefes Arch Clin Exp Ophthalmol; 2007 Nov; 245(11):1727-30. PubMed ID: 17690897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab for retinopathy of prematurity.
    Lim LS; Mitchell P; Wong TY
    N Engl J Med; 2011 Jun; 364(24):2360; author reply 2361-2. PubMed ID: 21675897
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.
    O'Keefe M
    Ir Med J; 2011; 104(7):197. PubMed ID: 21957683
    [No Abstract]   [Full Text] [Related]  

  • 15. Bevacizumab for retinopathy of prematurity.
    Reynolds JD
    N Engl J Med; 2011 Feb; 364(7):677-8. PubMed ID: 21323546
    [No Abstract]   [Full Text] [Related]  

  • 16. Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity.
    Lalwani GA; Berrocal AM; Murray TG; Buch M; Cardone S; Hess D; Johnson RA; Puliafito CA
    Retina; 2008 Mar; 28(3 Suppl):S13-8. PubMed ID: 18317338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comment on "Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity".
    Er H
    Retina; 2009 Oct; 29(9):1380; author reply 1379-80. PubMed ID: 19934833
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical factors related to recurrence of anterior segment neovascularization after treatment including intravitreal bevacizumab.
    Saito Y; Higashide T; Takeda H; Murotani E; Ohkubo S; Sugiyama K
    Am J Ophthalmol; 2010 Jun; 149(6):964-972.e1. PubMed ID: 20381786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Molecular pathogenesis of ocular vascular disease--anti-angiogenesis as a therapeutic concept].
    Joussen AM
    Dtsch Med Wochenschr; 2007 Jun; 132(23):1268-72. PubMed ID: 17541869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Bevacizumab: progress in the treatment of metastatic cancer and hope for patients with proliferative retinopathy].
    Antoniak K; Nowak JZ
    Postepy Hig Med Dosw (Online); 2007 May; 61():320-30. PubMed ID: 17554235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.